What the FDA labels say about taking them together
Eptifibatide and heparin
Eptifibatide's FDA label of May 28, 2021 names heparin in its drug interactions section, and heparin's label names eptifibatide too. The eptifibatide label: “If heparin is given concomitantly, monitor aPTT or ACT.”
Check it at the source: the eptifibatide FDA label on DailyMed (effective May 28, 2021, Mylan Institutional LLC); the heparin FDA label on DailyMed (effective November 28, 2025, Fresenius Kabi USA, LLC).
What does the eptifibatide label say about heparin?
Eptifibatide label, drug interactionsCoadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding.
Eptifibatide label, warnings and precautionsIf heparin is given concomitantly, monitor aPTT or ACT.
Source: FDA drug label (Eptifibatide), Mylan Institutional LLC, effective May 28, 2021 (SPL set 88a37f9c-496b-4a6b-9665-4550abba04f1), via openFDA; the full label on DailyMed
What does the heparin label say about eptifibatide?
Heparin Sodium label (Fresenius Kabi USA, LLC, April 30, 2026), drug interactionsDrugs such as NSAIDS (including salicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
Source: FDA drug label (Heparin Sodium, NDA017029), Fresenius Kabi USA, LLC, effective April 30, 2026 (SPL set 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5), via openFDA
Source: FDA drug label (Heparin Sodium In Sodium Chloride, NDA018609), Baxter Healthcare Corporation, effective January 3, 2022 (SPL set 0d929726-76c3-48fc-b4e7-fd06409f9fb3), via openFDA
Source: FDA drug label (Heparin Sodium), Fresenius Kabi USA, LLC, effective November 28, 2025 (SPL set d55b4a63-0c04-4874-b74f-9e9b9e8b008c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Eptifibatide | Heparin | |
|---|---|---|
| Labeled for | Heart attack and coronary artery disease | Blood clots (DVT and PE), Atrial fibrillation |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $1.18 per mL 5,000 unit/mL vial |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once